Soon to merge CMO Patheon has increased solid dosage form production capacity at its site in the UK and posted an improved set of preliminary results for the financial year.
The US FDA has defined compounding pharmacies as ‘outsourcing facilities’ in new guidance issued days after the Drug Quality and Security Act (DQSA) became law.
Apotek Produktion & Laboratorier AB (APL) says manufacturing knowledge and drug delivery tech knowhow gained by its compounding business is a boon for its CMO unit.
As part of its global streamlining strategy a second Irish Merck & Co plant has been earmarked to close but the firm says it remains committed to Ireland.
Actavis says it is restructuring a Californian manufacturing facility at a cost of 56 jobs weeks after the announced closure of a plant in North Carolina.
Catalent says it is creating dedicated space and possibly jobs at its Missouri facility in order to service a commercial contract for Pharmacyclics’ oncology drug Imbruvica.
Unilife has signed a $40m long-term supply agreement with Hikma and says it is committed to becoming the world’s largest and most successful injectable drug delivery systems supplier.
Pfizer says it intends to shutter a manufacturing facility in Puerto Rico just days after Merck & Co. announced it was reducing its footprint on the island.
Particle Sciences has been tasked with creating a nasal formulation of the steroid hormone progesterone that can be used to treat patients who have suffered traumatic brain injury.
The high cost of energy in the UK is having a negative impact on drug and chemical firms' ability to compete according to manufacturers quizzed by the Chemical Industries Association (CIA).
Royal DSM wants to merge its pharmaceutical products business with Patheon and has signed a deal with the latter's owner, investment group JLL Partners.
AstraZeneca says it would never outsource the manufacture of Zoladex after announcing plans to invest £120m ($190m) in a fifth production facility for the blockbuster cancer drug.
West says it is one step closer to bringing the Daikyo Crystal Zenith (CZ) drug delivery system to commercialisation with the completion of a first-in-man study.
The US FDA is working with GEA to validate continuous manufacturing as the pharma industry enters “the start of the end” for batch manufacturing, according to GEA.
There are multiple ways to make amorphous dispersions in order to enhance bioavailability but spray dry dispersion (SDD) is often the most applicable, Bend Research says.
Bend Research is expanding its commercial spray-dried dispersion (SDD) manufacturing with capital from new owners Capsugel in order to offer unique integrated capabilities, the firm says.
CatScI says pharma demand for catalysis services is increasing due to a greater focus on economic sustainability as it inks a deal with SAFC for its chemical processes.
Remediation at troubled Rocky Mount facility will continue into 2014 Hopira says as it awaits an inspection by the US Food and Drug Administration (FDA).
The US FDA and European Medicines Agency (EMA) is now offering additional joint guidance on the concept of quality-by-design (QBD) that focuses mostly on design space verification.
A third Amarin supplier has confirmed it will continue to supply the firm with pharma-grade omega-3 despite a US FDA panel recommending against a label extension for the heart pill Vascepa.
Persistence, endurance and a steadfast focus has led to AMRI receiving a close-out letter for its long suffering Burlington, Massachusetts facility, the company says.
Novartis has confirmed it is closing a UK facility as part of a global R&D review but remains silent on rumours specific business units will be divested.
DSM says it has not found the right partner for its pharmaceutical products business and is continuing to look for a collaborator with which it can grow in Asia.
Copley Scientific expects the new version of its flow rate control technology for dry powder inhaler (DPI) testing to be in demand among both generic drug firms and pharmaceutical innovators.
Merck & Co intends to close ten more manufacturing plants to further shrink its footprint as it continues to restructure after its 2009 megamerger with Schering-Plough.
Granules India has outlined plans to buy drug intermediate and API maker Auctus Pharma, set up an actives R&D site and announced its intention to wind up its ‘shell’ operation in Singapore.
The acquisition of Bend Research by Capsugel may be “a marriage made in heaven” for customers, the firms say, as the first drug delivery tech is transferred.
Dow says the acquisition of partner Bend Research is “good news” and will strengthen its developments in solving solubility and bioavailability issues in drug formulation.
Patheon brought in McKinsey consultants over the last three years to help overhaul its sagging business and institute a number of simple process changes that resulted in deep transformations.
Indian manufacturing heavyweight Mylan Laboratories is looking to build off its major acquisition of Agila with a number of smaller acquisitions, while Natco is about to receive a cash infusion for manufacturing expansions.
Ben Venue’s closure is still being evaluated the troubled drugmaker says, in the week the European Medicines Agency (EMA) is meeting to discuss ongoing shortages.
Teva subsidiary Pliva has opened a new $100m (€73m) oral dosage manufacturing facility in Zagreb, Croatia to increase its export of tablets and capsules to the US and EU.
Linking peptide and small molecule drugs to albumin will improve pharmacokinetics, says Almac as it partners its manufacturing capabilities with Novozymes’ half-life extension platform.
US contractor SAFC has joined the growing list of drugmakers and CMOs to invest in ADCs by announcing plans to add commercial-scale production capacity.
